Open AccessComparison of Two Different Fibrinogen Concentrates in an in vitro Model of Dilutional Coagulopathy
Author(s) -
Philipp Groene,
Tobias Wiederkehr,
T Kämmerer,
Patrick Möhnle,
Melanie Maerte,
Andreas Bayer,
Klaus Görlinger,
Markus Rehm,
Simon Schäfer
Publication year - 2019
Publication title -
transfusion medicine and hemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 39
eISSN - 1660-3818
pISSN - 1660-3796
DOI - 10.1159/000502016
Subject(s) - hydroxyethyl starch , thromboelastometry , fibrinogen , clotting time , coagulopathy , diluent , coagulation , medicine , thrombin time , chemistry , pharmacology , anesthesia , chromatography , partial thromboplastin time , surgery , nuclear chemistry
Fibrinogen concentrates are widely used to restore clot stability in situations of bleeding. Fibrinogen preparations are produced using different production methods, resulting in different compounds. Thus, different preparations might have a distinct impact on blood coagulation. We tested the effect of fibrinogen concentrates Haemocomplettan® (CSL Behring, Marburg, Germany) and fibryga® (Octapharma GmbH, Langenfeld, Germany) on the impairments induced by 60% dilutional coagulopathy in vitro.